Post by Idorsia Pharmaceuticals Ltd

Today we reported new positive results with our investigational C. difficile vaccine. “Our data show strong dose-dependent immune responses against a glycan target present on both bacteria and spores,” said our Chief Scientific Officer and Head of Research, Martine Clozel. “This underscores the potential to go beyond traditional approaches and target the full life cycle of the pathogen.” Read the media release: https://bit.ly/idiamr